Topotarget A/S Copen (TPTGF) 0.5800 $TPTGF Therapeutic

New Post Public Reply Private Reply Replies (0) Message Board

Mar 29, 2014 at 9:10 PM

Topotarget A/S Copen (TPTGF) 0.5800 $TPTGF

Therapeutic Report for Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
M2 - Tue Aug 06, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sqnpw/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the acute lymphocytic leukemia therapeutic pipeline. It provides information on the therapeutic development for acute lymphocytic leukemia complete with latest updates, and special features on late-stage and discontinued projects. The document is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for acute lymphocytic leukemia. - A review of the acute lymphocytic leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the acute lymphocytic leukemia pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for acute lymphocytic leukemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding acute lymphocytic leukemia pipeline depth and focus of acute lymphocytic leukemia therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Acute Lymphocytic Leukemia Overview Therapeutics Development An Overview of Pipeline Products for Acute Lymphocytic Leukemia Companies Involved in Acute Lymphocytic Leukemia Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned (40) Including: - 4SC AG - Ariad Pharmaceuticals - Bio-Path Holdings - Bristol-Myers Squibb Company - CanBas Co - Exelixis - F. Hoffmann-La Roche - Genzyme Corporation - Hana Biosciences - Incyte Corporation - Jazz Pharmaceuticals - KaloBios Pharmaceuticals - Lentigen Corporation - Millennium Pharmaceuticals - MorphoSys AG - Mundipharma International - Novartis AG - Onconova Therapeutics - Oryzon - Pfizer - Proacta - Sigma-Tau Pharmaceuticals - SuperGen - SymbioTec GmbH - Threshold Pharmaceuticals - TopoTarget A/S - Tragara Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/5s...ymphocytic

T-Cell Lymphomas - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pz4gz2/tcell_lymphomas) has announced the addition of the "T-Cell Lymphomas - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for T-Cell lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell lymphomas. The document is built using data and information proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for T-Cell lymphomas. - A review of the T-Cell lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the T-Cell lymphomas pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for T-Cell lymphomas. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding T-Cell lymphomas pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage T-Cell Lymphomas Overview Therapeutics Development An Overview of Pipeline Products for T-Cell Lymphomas Companies Involved in T-Cell Lymphomas Therapeutics Development T-Cell Lymphomas - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Abbott Laboratories - Allos Therapeutics, Inc - Amgen Inc - Celgene Corporation - Cephalon - Chipscreen Biosciences Ltd - Eisai Co - Emergent BioSolutions Inc - Incyte Corporation - Kyowa Hakko Kirin Co - Millennium Pharmaceuticals - Mundipharma International Limited - Nerviano Medical Sciences - PharmaMar - Pharmacyclics, Inc - Sareum Holdings - Seattle Genetics, Inc - TopoTarget A/S - Xencor, Inc - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/pz..._lymphomas

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013
M2 - Fri Apr 12, 5:22AM CDT
Research and Markets has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013" report to their offering. 'Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL). Scope - A snapshot of the global therapeutic scenario for Peripheral T-Cell Lymphomas (PTCL). - A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects o

Soft Tissue Sarcoma - Pipeline Review, H2 2012
M2 - Mon Jan 07, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/f4g9mh/soft_tissue) has announced the addition of Global Markets Direct's new report "Soft Tissue Sarcoma - Pipeline Review, H2 2012" to their offering. 'Soft Tissue Sarcoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Soft Tissue Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma. Soft Tissue Sarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Reasons to buy - Identify and understand important and di

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ingram Micro Joins S&P SmallCap 600 Amid M&A Moves

Market Shufflin’ as Ingram Micro Steps In The constant ebb and flow of the stock market got right interesting with Ingram Micro Holding Corp. (NYSE: INGM) slated to crawl into the S&P SmallCap 600. This dance change-up is all thanks to Viatris Inc. (NASD: VTRS) looking to wrap up its acquisition of Pacira BioSciences (NASD: PCRX). With this deal sealing the fate of...

WOLFX App Aims to Tackle College Loneliness Head-on

Revolutionizing the College Experience The college years, man; they're supposed to be the best of your life, but for too many, they're just a lonely slog. Enters WOLFX, a student super app trying to tackle loneliness and isolation head-on. It's already spreading its wings at 116 universities, aiming to knit students together without the noisy distraction of mainstream...

Gilbert Welcomes Luxury Florals: French Florist Expands

A Fresh Bloom in Gilbert: French Florist Steps In Toss aside your preconceived notions of what a florist shop should be. When French Florist sets up shop, it's not just about selling flowers—they’re a game-changer in the floral industry. As of November 4, they've stamped their luxury mark in Gilbert, Arizona, courtesy of Ronny and Nicole Record, who aren’t your...

Claus for a Cause: Respecting Heroes with Holiday Cheer

An Unforgettable Holiday Season Veterans Day isn't just a date on the calendar—it's an opportunity to pause and offer genuine thanks to those who've served with honor. This year, as the holiday season rolls around, Gemmy Industries' Claus for a Cause collection is redefining how we show our appreciation. These aren't your ordinary inflatables; they come with a purpose...

Wisconsin Winters: The Art of Navigating Construction Delays

Winter's Cold Grasp on Construction Efforts Alright, folks, let's dive into a topic as chilling as a Wisconsin winter itself—those icy weather conditions that builders have to wrangle with each year. You might think snowflakes have got nothing on a solid timeline, but too much snow? That changes the game, my friends. Right off the bat, Kyle Tielens, the know-it-all of...

Community Dental Programs Bridge Care Gaps Effectively

Community Dental Programs: A Collaborative Force for Change Kicking around the same old healthcare conundrum, aren't we? But here's the kicker—dental care, of all things, gets a fierce spotlight today. We're diving into how community dental programs, backed by the grit of professionals like Dr. Erin Beveridge Cabuling and Dr. Monica Wu, make a serious dent in improving...

Spain's Young Entrepreneurs Get a Boost from Temu

Paving New Paths for Spanish Startups Temu and CEAJE are shaking hands to jumpstart a new era for Spanish entrepreneurs, promising to flip the script on digital growth and international outreach. This partnership is a big deal, aiming to leverage both parties' strengths to provide young business owners across Spain with the tools they need to ride the digital wave. A...

Shanghai's Sports Vision: Bold 2030 Targets Loom

Shanghai's Sporty Vision: Lofty Targets Set for 2030 In a move that could shake things up in the global sports arena, Shanghai has laid out its latest five-year plan, aiming to become a renowned sports hub by 2030. If you're wondering what that means beyond whistles and scoreboards, let me break it down. This isn't just about a running track or two; it's about crafting an...

Epson Unveils Early Black Friday Tech Deals

By Evelyn Baker Updated Nov 11, 2026 Category News Views 122

Diving Headfirst into Holiday Tech Splurging The holiday hustle is upon us, folks, and Epson's stepping up with early Black Friday deals that'll have tech heads scrambling. They’re cutting prices up to $250 on their swanky home lineup—projectors, printers, scanners, you name it. This ain't just about making someone else smile, though; it's about the sweet spot where...

Lightwave Logic Delays Spur Legal Investigation

Lightwave Logic Faces Legal Hurdles There's trouble brewing for Lightwave Logic, Inc. (NASDAQ: LWLG) after its decision to push back volume production to 2028 stirred the pot. Shares took a nosedive, opening down by about 15% at $3.73, after the company revealed their foundry process and customer qualifications were dragging at a snail's pace. And as you might expect,...